AbbVie says FDA reviews Skyrizi subcutaneous induction dosing for Crohn’s disease
AbbVie said subcutaneous induction dosing for Crohn’s drug Skyrizi is under regulatory review by the FDA and EMA. The company cited Phase 3 AFFIRM data showing week 24 endoscopic remission of 35.8% on Skyrizi vs 9.1% on placebo. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative arti